Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Schering acquires Japanese Alzheimer's imaging agents

This article was originally published in Scrip

Executive Summary

Bayer Schering Pharmahas licensed from the University of Nagasaki in Japan a series of molecules for use in the positron emission tomography imaging and diagnosis of Alzheimer's disease. The fluorine-18-labelled tracers bind to amyloid beta protein, the accumulation of which has been linked to the development of the disorder. At present, a diagnosis can only be confirmed through autopsy; the molecular imaging agents may enable much earlier detection and treatment, said the company, which holds exclusive global development and marketing rights.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC032204

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel